Aviva
NEO icon

Aviva’s NeoGenomics NEO Stock Holding History

Aviva’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,960
Closed -$1.2M – 943
2021
Q1 		$1.2M Buy
+24,960
New +$1.3M 0.01% 843

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Aviva's NEO Position: Q2 2021 in Review

Aviva sold out of NeoGenomics (NEO) in Q2 2021, closing a stake of 24,960 shares — an estimated $1.2M sold.

Aviva first reported a position in NEO in Q1 2021 and held it in 1 quarter. The position peaked at $1.2M in Q1 2021. 311 funds tracked by Wall St. Rank hold NEO as of Q2 2021.

  • Aviva reported no remaining NeoGenomics position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 24,960 NeoGenomics shares in Q2 2021, an estimated $1.2M.
  • Aviva first reported a position in NeoGenomics in Q1 2021 and held it in 1 quarter.
  • Aviva's NeoGenomics position peaked at $1.2M in Q1 2021.
  • 311 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.